Key Takeaways
- Solid FY26, margin story intact: Revenue grew 13% to ₹887 crores while EBITDA margin reached 20%, driven by backward integration and a favorable product mix, even as Q4 gross margin dipped on a solvent cost spike.
- Backward integration is the structural moat: Management stated the company would not have survived current market conditions without its ibuprofen backward integration, which stabilized both margins and customer confidence.
- FY27 guided at 15% growth, with upside: The official guide is conservative, with management’s internal target at 20–25% if the external environment stabilizes; the brownfield expansion will not contribute until FY28.
- Portfolio actively reshaped toward high-margin molecules: Resources were consciously redirected away from anti-diabetics into ARVs and anti-inflammatories, while a brownfield expansion and peptide R&D build the next growth leg.
- What to watch next quarter: Progress on the 10 DMF/CEP filings targeted for FY27, clarity on the peptide commercial roadmap, and whether the solvent cost pressure that hit Q4 gross margin persists.
Performance & Margin Drivers
- Revenue growth led by two segments: Anti-inflammatory APIs saw progressive volume growth with a significant portion of planned capacity already committed for the coming year, while the ARV segment gained market share on a superior cost structure and saw encouraging traction from recently commercialized products.
- Q4 gross margin hit from an external shock: Gross margin declined 2% QoQ due to a drastic increase in solvent costs in March, driven by the war; this was a raw material consumption spike, not a structural cost problem.
- EBITDA margin expanded for the full year: FY26 EBITDA margin reached 20%, reflecting benefits of backward integration, a favorable product mix and operating leverage, despite the Q4 solvent headwind.
- Anti-diabetic retreat was deliberate: Management proactively adjusted strategy at the beginning of Q3 FY26, before pricing and demand impact became visible, and consciously redirected resources to ARVs and anti-inflammatory APIs where stronger long-term opportunities exist.
- Customer concentration is diversified within the relationship: The largest customer contributes 28% of total revenue, but from multiple products rather than a single product, reducing single-molecule dependency risk.
Potluri: "if we have not backward integrated, like we've not taken this call of backward integration a couple of years back, we would have probably been in a very bad situation now because of the current market scenarios, because of price escalations, we wouldn't have been able to survive in the market."
Growth Pipeline: Brownfield, Peptides & CDMO
- Brownfield expansion on track for FY28 revenue: Against a total planned investment of ~₹280 crores, ₹130 crores has already been invested; the project includes multiple high-margin molecules expected to generate profitability above the current portfolio average, with completion by March FY27 and incremental revenues from FY28.
- Capacity utilization to ramp through FY28: Management expects to reach a high level of utilization by FY28, with brownfield products beginning to contribute meaningfully during FY28 and scaling further in FY29.
- Peptides in early R&D, commercial path forming: The company has already invested in R&D capabilities with promising initial results across multiple products; greater clarity on the commercial roadmap is expected after the next two quarters, with meaningful contributions from FY29 onwards.
- CDMO initiative progressing, update pending: The project is progressing well with continued evaluation of opportunities and capability building; management will be in a better position to provide a comprehensive update after the next two quarters.
- JV with Chemo adding five products: Five new products are being developed for the JV and are expected to be commercialized in FY27.
- Regulatory filings to sustain the pipeline: 10 additional DMF/CEP filings are targeted in FY27, with a further 10 filings planned for FY28.
Related-Party Ecosystem
- VKT Pharma is a captive customer: VKT Pharma, in which SMS Pharma holds a 34–35% stake, buys APIs from SMS Pharma; the contribution is anticipated to be sustainable and strengthen into FY27.
- SMS Life Sciences is an upstream supplier: Promoters have an investment in SMS Life Sciences, a separate company from which SMS Pharma buys some intermediates and raw materials.
- No consolidation planned: Management stated there are no plans to bring VKT Pharma or SMS Life Sciences into the fold.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15% growth; potential to exceed if external environment stabilizes and logistics improve | FY27 |
| EBITDA margin | Improve upon FY26's 20%; target 22% | FY27 |
| Brownfield expansion completion | ~₹280 crores total investment, ₹130 crores already invested; completion and incremental revenues thereafter | Completion by Mar FY27; revenues from FY28 |
| DMF/CEP filings | 10 filings | FY27 |
| DMF/CEP filings | Further 10 filings | FY28 |
| JV product commercialization | Five new products | FY27 |
| Peptides commercial roadmap clarity | Greater clarity expected | After next 2 quarters |
| CDMO comprehensive update | Better position to provide update | After next 2 quarters |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹238 cr |
| Full-year revenue | ₹887 cr, +13% YoY |
| Gross profit | ₹81 cr |
| Full-year gross profit | ₹303 cr, +14% YoY; gross margin at 34% |
| EBITDA | ₹40 cr, margin at 17% |
| Full-year EBITDA | ₹171 cr, +23% YoY; margin at 20% |
| PAT | ₹33 cr, including ₹12 cr from associate VKT Pharma; excluding that, PAT at ₹21 cr |
| Full-year PAT | ₹102 cr, +47% YoY, including ₹14 cr from VKT Pharma; excluding VKT Pharma, PAT grew 28% to ₹88 cr |
| FY27 revenue growth guidance | 15%, with potential to exceed if external environment stabilizes |
| FY27 EBITDA margin target | 22%, aiming to improve upon FY26 margin of 20% and reach historical high |
| Installed capacity (post capex) | 800 metric tons per month, increasing from 500 tons; completion by March FY27 |
| Current capacity utilization | ~80% |
| High-value product share | 47% of total sales, expected to reach around 60% |
| Export share | 70% of business, expected to remain in 70–75% range |
| Ibuprofen revenue contribution | ~20% of total revenue |